SXTP and SXTPW Related Headlines
Go Back- 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
- 60 Degrees Pharmaceuticals raises $1M in private placement
- 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
- 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
- 60 Degrees Pharma signs option deal with Florida State for tick disease compound
- 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
- 60 Degrees Pharma gets safety board clearance for babesiosis trial
- 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
- 60 Degrees Pharmaceuticals licenses Australian chestnut patent
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
- 60 Degrees Pharmaceuticals enrolls first patient in tafenoquine babesiosis trial
- 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
- 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
- 60 Degrees Pharma makes malaria drug available on telehealth platform
- 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
- 60 Degrees Pharmaceuticals Announces 2025 Annual Results
- 60 Degrees Pharmaceuticals files FDA notification for dietary supplement
- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
- 60 Degrees Pharmaceuticals reports babesiosis cures in small trial
- 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
- 60 Degrees Pharmaceuticals partners with GoodRx for ARAKODA discounts
- 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
- 60 Degrees Pharmaceuticals exercises license option for castanospermine
- 60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
- 60 Degrees Pharmaceuticals partners with Runway Health for malaria drug
- 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
- 60 Degrees Pharmaceuticals to implement 1-for-4 reverse stock split
- 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
- 60 Degrees Pharmaceuticals finds Babesia in 24% of chronic fatigue patients
- 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
- 60 Degrees Pharmaceuticals plans ARAKODA sales expansion for 2026
- 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
- 60 Degrees Pharmaceuticals opens site for chronic babesiosis study
- 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
- 60 Degrees Pharmaceuticals reports first patient clears babesia infection
- 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
- 60 Degrees Pharmaceuticals names chronic babesiosis trial B-FREE
- 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
- Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
SXTP and SXTPW Related Press Releases
Go Back- 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
- 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
- 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
- 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
- 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
- 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
- 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
- 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
- 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
- 60 Degrees Pharmaceuticals Announces 2025 Annual Results
- 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
- 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
- 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
- 60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
- 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
- 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
- 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
- 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
- 60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
- 60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study
- 60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study
- Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
